Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Novy Hradec Kralove – page 8

207 clinical trials in Novy Hradec Kralove, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Novy Hradec Kralove at a glance
207
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

207 trials in Novy Hradec Kralove

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Neovascular age-related macular degeneration

Not recruiting

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Urinary tract infection+1

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Encephalitis autoimmune

Not recruiting

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Chronic myeloid leukaemia (in remission)

Not recruiting

Study on Stopping Nilotinib, Imatinib, and Dasatinib in Patients with Chronic Myeloid Leukemia in Deep Remission

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Masarykova Univerzita

Breast cancer metastatic

Not recruiting

Study of Disulfiram and Copper for Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Disulfiram
  • Sponsor:Univerzita Palackeho V Olomouci

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:CLS12311
  • Sponsor:Cellerys AG

Plasma cell myeloma

Not recruiting

Study on the Effects of Isatuximab with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma refractory

Not recruiting

Study of belantamab mafodotin, bortezomib and dexamethasone combination in adults with relapsed or refractory multiple myeloma who received at least one prior therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Ceska Myelomova Skupina z.s.

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Novy Hradec Kralove

What the registry says about research in the country

01 Neurological Disorders

Clinical trials focusing on multiple sclerosis and Alzheimer's disease, evaluating novel therapeutic approaches including comparative studies of treatments like frexalimab and investigations of cognitive performance in early-stage Alzheimer's patients with inflammation markers.

  • Relapsing Multiple Sclerosis
  • Early Alzheimer's Disease
  • Neuroinflammatory Conditions

Studies aim to assess treatment efficacy and disease progression markers.

02 Hematologic Malignancies

Comprehensive research into blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and various lymphomas, testing innovative combination therapies and treatment approaches.

  • Leukemia Treatment Protocols
  • Lymphoma Management
  • Novel Drug Combinations

Focus on improving survival rates and treatment outcomes for blood cancer patients.

03 Respiratory Conditions

Studies examining treatments for chronic rhinosinusitis and uncontrolled asthma, with trials evaluating new medications like brensocatib and AZD8630 for symptom management and disease control.

  • Nasal Symptoms Management
  • Asthma Exacerbation Prevention
  • Respiratory Disease Control

Research focused on improving quality of life for patients with chronic respiratory conditions.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.